Akebia Therapeutics Inc (AKBA): Navigating Revenue Declines and Unlocking Growth Potential
In a market where growth is the holy grail, Akebia Therapeutics Inc (NASDAQ: AKBA) has been making headlines with its impressive 27.56% surge today. As we dive into the company's Q4 2024 earnings call highlights, it becomes clear that this biopharmaceutical firm is...